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Promoting best practice in the management of a cancer patient is rooted in the
application of new knowledge derived through various sources including population
science, laboratory advances, and translational research. Ultimately, the impact of these
advances depends on their application at the patient’s bedside. A close collaboration
between the oncologist and the pathologist is critical in underwriting progress in the
management of the cancer patient. Recent advancements have shown that more
granular characteristics of the tumor and the microenvironment are defining determinants
when it comes to disease course and overall outcome. Whereas, histologic features
and basic immunohistochemical characterization were previously adequate to define the
tumor and establish treatment recommendation, the growing capability of the pathologist
to provide molecular characterization of the tumor and its microenvironment, as well
as, the availability of novel therapeutic agents have revolutionized cancer treatment
paradigms and improved patient-outcomes and survival. While such capacity and
capability appear readily available in most developed high-income countries (HIC), it
will take a concerted and collaborative effort of all stakeholders to pave the way
in the same stride in the low and middle-income countries (LMIC), which bear a
disproportionate burden of human illness and cancers. Patients in the LMIC present with
disease at advanced stage and often display characteristics unlike those encountered
in the developed world. To keep stride and avoid the disenfranchisement of patients in
the LMIC will require greater participation of LMIC patients on the global clinical trial
platform, and a more equitable and affordable sharing of diagnostic and therapeutic
capabilities between the developed and developing world. Key to the success of this
progress and improvement of patient outcomes in the developing world is the close
collaboration between the oncologist and the pathologist in this new era of precision and
personalized medicine.
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THE CRITICAL INTERPLAY BETWEEN
PATHOLOGY AND ONCOLOGY

Denkert and colleagues (17) were the first to demonstrate
that a high Tumor Infiltrating Lymphocyte (TIL) count in
breast cancer tissues was associated with a significant pathologic
complete remission (pCR) rate following Neoadjuvant therapy
compared to TIL low tumors. Higher levels of TILs also predict
for increased responsiveness to chemotherapy independent of
estrogen receptor (ER), progesterone receptor (PR), and Human
Epidermal Growth Factor Receptor (HER2), with each 1%
increment associated with a further increase in the rate of
pCR (18).
The role of the pathologist has thus evolved beyond the
characterization of the tumor itself and moved on to include the
non-clonal cellular microenvironment surrounding the tumor.

There is no better example of the critical interconnectedness
between the pathologist and the clinician than in the field of
oncology. Decades ago, the primary support function of the
pathologist working with the oncologist was in the diagnostic
identification and characterization of an identified malignancy.
Categories were rather broad, e.g., carcinoma; sarcoma;
myeloma; leukemia; and lymphoma (1) with additional features
allowing carcinomas to be categorized into adenocarcinoma vs.
squamous cell carcinoma (2). The organ of origin was often
deduced based on the histologic features of the tumor on H.E.
Stain and supporting clinical as well as radiologic features (3).
Advances in immunohistochemistry and the identification of key
surface markers have enabled a more nuanced characterization of
tumors enabling site of origin as well as well as cellular markers
of proliferation that add prognostic significance (4). Advances in
molecular testing has added a new layer of capability to identify
unique molecular characteristics of the tumor that in turn can
provide clues into the molecular mechanism of the malignancy
as well as point toward potentially effective therapies based on
such predictive markers (5).
More recently, with the advent of NextGen Sequencing (NGS)
pathologists have the capability of providing the oncologist
critical actionable information directly relevant to the treatment
and prognosis of the patient with cancer (6–8). Such advances
have shored up the critical interconnectedness between the
pathologist and the oncologist. This interplay is best observed
at the tumor boards where peer discussion and treatment
recommendation is heavily dependent on the contribution of the
pathologist, wherein therapeutic decision making is based not
just on the histologic features and immunohistochemical markers
but in addition on predictive molecular characteristics of the
tumor (9).

IMMUNOTHERAPY AND THE ROLE OF
THE PATHOLOGIST
Immunotherapy has become an indispensable arm of cancer
management with novel T-cell targeting agents approved by
the FDA across various indications both as single agents or in
combination with conventional cytotoxic agents (19).
The Nobel Prize in Medicine or Physiology awarded in 2018
acknowledged the important contributions of James Allison
and Tasuku Honjo, for their pioneering work on cancer
immunotherapy (20). Hailed as a revolution in the treatment
of cancer, immunotherapy works by boosting the body’s natural
defenses against cancer. The Nobel committee heralded the
efforts of the two scientists as establishing an entirely new
principle for cancer therapy by stimulating the inherent ability
of our immune system to attack tumor cells (21, 22).
These advances could not have been possible without the
investigative role of the pathologist giving importance to
not just the tumor cells but to the surrounding TME and
tumor infiltrating T-cells (23). The role of the pathologist in
investigating the TME in an objective reproducible way is best
exemplified by the Programmed Cell Death Ligand combined
positivity score (PDL1-CPS)which has become critical as a
companion diagnostic tool for the use of a number of novel
immunotherapy agents approved by the FDA (24). In the
years to come the need for tumor NGS and TME in forging
new therapeutic advances will become increasingly evident and
critical (25).

IMPORTANCE OF THE TUMOR
MICROENVIRONMENT (TME)
Stromal processes play a critical role in cancer biology and in
some cases, may predict the clinical course of a malignancy
better than cellular characteristics of the neoplastic cells
itself (10, 11). The tumor microenvironment is a dynamic
network that includes the tumor cells, stromal tissue within
which are the immune cells, fibroblasts, pericytes, cytokines,
and tumor vasculature and the extracellular matrix (12).
In addition to epithelial and stromal compartments, the
tumor microenvironment contains several cell types of the
innate and adaptive immune systems including B and T
lymphocytes, dendritic cells, and macrophages (13). This
tumor microenvironment (TME) provides added dimension
that influences both the biology of the tumor as well as its
response to therapeutic efforts and the development of resistance
(14). It is integrally involved in nearly all processes critical
to the malignant process -tumor initiation, growth, migration,
metastasis, and therapeutic resistance (15, 16). As an example,
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CLOSING THE GAP- ACCESS TO
MOLECULAR DIAGNOSTICS
The recent advances in molecular diagnostics have contributed to
an increasing disparity between patients in the West and those in
the developing world where access to such technology remains
wanting, both because of lack of trained pathologists with
molecular sub-specialization but also as a result of lack of testing
facilities within sub Saharan Africa (26, 27). One solution toward
bridging this gap is the establishment of collaboration between
pathology departments in the LMIC with molecular diagnostic
laboratories in the West and the creation of virtual molecular
tumor boards both as a platform for peer discussion and capacity
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patient provides a novel platform to discuss all aspects of the
patient management journey in one setting. Our experience at
AKUHN has demonstrated that >90% of patients and family
members wish to participate in a multi-disciplinary consultation
that is provided at no extra charge. Patients get to voice their
input and buy-in for the proposed treatment plan. Interestingly,
in 20% of the cases, patient preferences result in modification
of the treatment plan both in terms of surgical management
or selection of neoadjuvant vs. adjuvant therapy. In 10% of
cases, patients have desired additional psycho-social counseling
and in 10% of cases patients requested nutritional and dietary
counseling. A summary of the data collected from the MBC
clinics at AKU is provided (Figure 1). This platform also serves
as an ideal setting to inform patients about clinical trials and
to initiate the informed consent process for ongoing research
studies including clinical trials.

building (28). Part of the impetus for such collaboration may
well be the heightened interest in the molecular characterization
of cancers diagnosed in the African continent (29). As part
of the research collaboration, institutions in SSA could receive
access to subsidized Next Generation Sequencing (NGS) of their
tumor samples, participation on virtual molecular tumor boards
where such cases can be discussed, as well as, opportunity for
the patients to participate on clinical trials (30). An important
component that would effectively bridge this divide and result in
actionable benefit to the African patient would be the availability
of novel therapeutic agents for the treatment of patients identified
to harbor unique actionable molecular features. Therein lies the
opportunity to enroll such patients onto clinical trials that offer
access to novel treatments that would otherwise not be available
to such patients.

MULTIDISCIPLINARY TUMOR BOARDS
AND SPECIALTY CLINICS

PROMOTING CANCER CLINICAL TRIALS
IN SSA

Tumor boards represent an ideal platform for data driven peer
discussion, both as a means to establish best practice for common
cancers, but also as a venue for the multi-disciplinary discussion
of complex cases in the context of existing resource limitations
(9). The incorporation of peer partners in virtual MDTs from
Western academic centers provides an important avenue for
sharing new knowledge as well as identifying areas of need
for diagnostic investment in the LMIC (31, 32). In addition,
such platform provide the opportunity for peer discussion
and knowledge transfer that ultimately making the optimal
therapeutic choice for the patient.
Beyond the multidisciplinary tumor boards, since January
2021, we have moved to establish specialty clinics dedicated for
the multi-disciplinary in-person consultation of patients with
specific cancers at the Aga Khan University Hospital Nairobi
(AKUHN). We piloted our project with patients presenting with
newly diagnosed breast cancer (33). The success of this program
resulted in the establishment of a similar platform for patients
with newly diagnosed prostate cancer.
The multi-disciplinary in-person clinics go one step beyond
the tumor boards and allow the patient to be seen by a
team of specialists, including their own primary oncologist.
In the case of the multi-disciplinary breast cancer clinic
(MBC) and multi-disciplinary prostate cancer clinic (MPC), the
consultant team includes a medical oncologist, breast surgeon
or urologist, radiation oncologist, and a team of nurses and
coordinators. The patient gets to be interviewed and examined
by an independent physician member of the team, who then
presents the case at the “huddle” where the tumor board
discussion and recommendation is revisited in the context of
the patient’s own input. The management decision from the
“huddle” is then conveyed to the patient and family who then
have the opportunity to ask questions relating to the entire
management plan.
Our experience at the Aga Khan University Hospital Nairobi
has demonstrated an enthusiastic embrace of the MBC and MPC
model. Interestingly, the multidisciplinary engagement with the
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Africa makes up 1/6 of the world’s population (34). Of the
2.7 million clinical trials conducted internationally, less than
a fraction of 1% are conducted in the African continent with
participation of African subjects (35). This disparity was further
unmasked during the Covid-19 pandemic when <2% of the
clinical trials linked to the pandemic were conducted in the
African continent (36) and African patients had limited access
to novel treatment approaches such as Tocilizumab, Remdesivir
or participation in convalescent plasma studies. Within Africa
itself, nearly 2/3 of the clinical trials are conducted either in
Egypt or South Africa with marginal presence in the remaining
44 countries within the continent (35). In the year 2019, of a total
of 109 oncology clinical trials initiated in Africa, most of these
were conducted in North or South Africa and out of which there
were only 6 conducted in Sub Saharan Africa sites (37).
The African continent has long been the platform for studies
investigating the prevention and treatment of communicable
diseases such as malaria, tuberculosis, HIV etc. However, with
the rise in the life expectancy across the continent and lifestyle
changes, we have witnessed a rise in the incidence and mortality
associated with non-communicable diseases, specifically cancer
(38). Establishing clinical trial centers in SSA with well-trained
and experienced staff can provide an ideal platform to conduct
cutting edge clinical trials in the African continent (39, 40).
Conducting therapeutic oncology trial not only levels the playing
field for patients in the African continent, provides patients in
SSA access to novel therapeutics and allows staff to be trained and
experience the unique toxicity profile of such molecules. For the
pharmaceutical industry this provides the opportunity to study
a patient population with a vastly different ethnic and genetic
background, which may well-influence both the toxicity as well
as the outcome of such therapeutic agents. Genetic diversity and
its impact on drug metabolism has long been demonstrated and
may well-impact how African patients tolerate and respond to
such novel anti-cancer therapies (41).
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FIGURE 1 | Summary of the data collected from the MBC clinics at AKUHN over a period of 6 months.

potentially contribute to the incidence and outcome of prostate
cancer in these populations (47). It is thus critical that the
development of novel therapeutics especially in oncology include
the participation of African patients in drug development trials. A
current low enrollment of 4% of minority patients in clinical trials
conducted in N. America could well be supported and augmented
if clinical trial sites in Africa were included (48).
A number of actions would have to be taken if Africa is to
become a major partner in drug development. Recent data from
the World Bank suggests that African countries invest <1% of
their GDP in research and development as compared to USA
that spends close to 3% (49). The absence of universal health
coverage, the lack of awareness and near absence of cancer
screening initiatives and inability to afford standard diagnostic
procedures contributes significantly to late presentation and early
death among African patients with cancer (38).

“There is increasing recognition of the need for pathologists
to be involved early in trial planning and design to ensure
methodological rigor in trials requiring sample collection,
procurement, storage, transportation and analysis” (42). The
recommendations for Interventional Trials 2013 Statement has
recently been expanded to include Pathology (SPIRIT-Path) (43).
“The guidelines allow investigators to comprehensively address
the cellular and molecular pathology aspects of trial protocols,
ensuring adequate skills and resources are available at trial
commencement and fully leverage the value of biospecimens for
translational research” (43).

UNDERSTANDING THE ROLE AND
CONTRIBUTION OF GENETIC DIVERSITY
Genetic variations may also be critical in determining effective
strategies for the diagnosis and treatment of cancers in patients
of African origin given increasing evidence of the molecular
diversity of tumors found in African patients as well as a different
risk profile as compared to their N. American counterparts
(29, 44). As an example, a study of triple negative breast
cancer comparing mRNA signatures of women diagnosed with
triple negative breast cancer in African women from Kenya
revealed a differential expression of both up-regulated as well as
down-regulated genes as compared to African American (AA)
and Caucasians women from Alabama (45). Similarly, another
study comparing AA and European Americans (EA) revealed
clear differences in tumor biology between the two groups
(46). A recent study looking at AA and EA found significant
genetic difference in patients with prostate cancer which may
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BRIDGING THE GAP
Of the 54 countries in Africa only 25 countries have functional
population based cancer registries through the AFCRN (African
Cancer Registry Network) program that was set up in the year
2012 (50). For decades, the burden, pattern and outcome of
cancer in Africa has been understudied. Even functional registries
face countless challenges that contribute to the data being
inaccurate and unrepresentative. These include generally poor
health care infrastructure, lack of a regular and accurate census
program, absence of vital statistics, lack of adequately trained
personnel and lack of cooperation/contribution from other
data sources (51). Computer-based medical information systems
also remain underdeveloped (51). Researchers with experience
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conducting studies in Africa have opined on the following
barriers: lack of infrastructure, financial and human capacity,
delays in regulatory and ethical reviews, complex logistical and
financial systems (52).
Another major hurdle facing SSA is the lack of training
of health care workers in the field of research. Out of 909
training institutions in Africa, only 20% offer training in clinical
investigation and research. All of these trainings are at post
graduate level and research is not part of the curriculum at the
undergraduate level. The vast majority (over 50%) of the training
institutions are in Kenya, Ethiopia, SA and Ghana (53).
Despite the large human population and disproportionate
burden of disease, Africa lacks the human resources necessary
to implement an effective cancer control program. Only 7
African countries have a pathologist to population ratio of
more than 1/1,000,000. This is in contrast to 1 pathologist
per 15–20,000 population in Europe and N. America (54).
A shortage of oncologists also exists in over 25 countries in
Africa with clinical oncologist to new patient ratios exceeding
>1,000 compared to <150 in the west. It is also astounding
to note that ∼8 countries in Africa including Sierra Leone,
Burundi and Togo have no clinical oncologists (55). At this
stage, unless the paradigm changes, it would take Africa over
400 years to catch up (54). In addition, this disparity is further
compounded by the lack of sophisticated molecular diagnostic
and treatment capabilities even in those countries that have
well-trained pathologist/Oncologists.
In the last decade there have been a number of initiatives
by pharmaceutical companies and western nations to establish
projects to improve the research capacity, infrastructure and
collaboration within SSA (56). Establishment of clinical trials
cooperative groups such as those in N. America and Europe
will be key to allowing Africa to leap frog and catch up with
Western partners. It remains crucial for governments, NGO
and clinicians themselves to invest efforts and funds toward the

establishment of a more robust cancer prevention and control
program in SSA.
As oncology moves from a one size fits all to a more nuanced
and personalized approach employing precision medicine
technology, the role of the pathologist and interconnectedness
with the oncologist, and the close interplay between the
pathology bench and the clinical bedside will become increasing
important. The pathologist is no longer just a distant consultant
involved with the tissue obtained at surgery. Nor is the modern
oncologist one who limits him or herself to interpreting the
pathology report and prescribing a treatment regime. There
is a growing need for the pathologist to become involved
at the bedside and understand the nature of the malignant
illness, and for the oncologist to better understand and interpret
clinical relevance of the technologies applied at the pathology
bench. The treatment of the cancer patient of the future will
depend on the clinical findings at bedside, interpretation of
sophisticated diagnostic studies, and the translation of modern
molecular diagnostics results. The successful treatment of the
cancer patient will depend heavily on the interconnectedness
between the pathologist and oncologist and the availability of
novel therapeutic, aided by the availability of clinical trials.
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